Keywords: sembiosys, gets, 5m, mannkind, plant-based, insulin, canada
SemBioSys gets $2.5M from MannKind for plant-based insulin
Article | 12 January 2009
Canada's SemBioSys Genetics says that US firm MannKind Corp has purchased an option to license rights to its proprietary plant-produced ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US Supreme Court says patent settlement can "sometimes" be illegal
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
